BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 17156651)

  • 1. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
    Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)].
    Noseda G; Darioli R; Keller U; Mordasini R; Shokry A; Schaffhauser B; Riesen W
    Schweiz Med Wochenschr; 2000 Jun; 130(23):889-95. PubMed ID: 10897490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
    Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes of blood lipids in colorectal cancer patients with coronary heart disease and value of lipid-lowering therapy with statins].
    Liang ZT; Wang XP; Zeng QT; Liao YH; Gao CY; Li MW
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):863-5. PubMed ID: 18504222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
    Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
    Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
    McKenney JM; McCormick LS; Schaefer EJ; Black DM; Watkins ML
    Am J Cardiol; 2001 Aug; 88(3):270-4. PubMed ID: 11472706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease.
    Santanu G; Suhrita P; Mookerjee S; Tania K; Mita S; Pramit G; Sharmila G; Miraj M; Debdutta M
    Indian Heart J; 2011; 63(5):434-7. PubMed ID: 23550422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia].
    Li XP; Gong HR; Zhao SP; Huang WY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Dec; 41(12):1006-9. PubMed ID: 24524601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
    McKenney JM; Jones PH; Bays HE; Knopp RH; Kashyap ML; Ruoff GE; McGovern ME
    Atherosclerosis; 2007 Jun; 192(2):432-7. PubMed ID: 17239888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
    Karalis DG; Ross AM; Vacari RM; Zarren H; Scott R
    Am J Cardiol; 2002 Mar; 89(6):667-71. PubMed ID: 11897207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.